Tobacco

Page 1

Lorillard Inc responds to proposed FDA deeming regulations for electronic cigarettes

Thursday, 24 Apr 2014 11:30am EDT

Lorillard Inc:Responded to proposed regulations published on April 24 by the USFDA regarding the electronic cigarette industry.Lorillard has long-supported reasonable science-based regulation of electronic cigarettes such as establishing minimum age-of-purchase requirements, setting product quality and safety standards, and listing of ingredients and other relevant consumer information.

Japan Tobacco Inc and Torii Pharmaceutical Co., Ltd launches Rio na tablets

Wednesday, 16 Apr 2014 11:08pm EDT

Japan Tobacco Inc:Torii Pharmaceutical Co., Ltd and Japan Tobacco Inc (JT) announces that Torii would launch Rio na tablets 250mg in Japan on May 12.Says it receives manufacturing and marketing approval of this drug for the indication of the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD) from the Japanese Ministry of Health, Labour and Welfare in Jan 2014.JT and Torii expect to contribute to treat hyperphosphatemia in patients with CKD, including dialysis and non-dialysis dependent CKD, through marketing Riona tablets in Japan.

Japan Tobacco Inc and Torii Pharmaceutical Co Ltd receive approval for hyperphosphatemia tablet Riona

Friday, 17 Jan 2014 02:00am EST

Japan Tobacco Inc and Torii Pharmaceutical Co Ltd:Says received manufacturing and marketing approval of Riona Tablets 250mg, which is jointly developed by the two companies, from the Japanese Ministry of Health, Labour and Welfare.Says the drug is indicated as an oral treatment for the improvement of hyperphosphatemia in patients1 with chronic kidney disease (CKD).Says Riona Tablets is a novel phosphate binder containing ferric citrate hydrate as the active pharmaceutical ingredient.

Japan Tobacco Inc Announces Elvitegravir (JTK-303) Receives EU regulatory Approval

Tuesday, 19 Nov 2013 01:00am EST

Japan Tobacco Inc announced that a novel HIV integrase inhibitor, the Company's original compound elvitegravir (JTK-303), has been approved by the European Medicines Agency (EMA). The drug is to be marketed as Vitekta in the European Union. Japan Tobacco Inc. The Company announced that a statement has been issued to this effect by Gilead Sciences, Inc. (Gilead) of Foster City, California, to which the Company licensed elvitegravir in March 2005 with exclusive rights to develop and commercialize the drug worldwide, excluding Japan.

Lorillard Inc Receives FDA Market Authorization for New Products

Tuesday, 25 Jun 2013 03:17pm EDT

Lorillard Inc announced that is has received notification from the U.S. Food and Drug Administration (FDA) that its Newport Non-Menthol Gold Box and Box 100 products have been found to be substantially equivalent to tobacco products previously commercially marketed in interstate commerce in the U.S. The FDA's finding permits Lorillard to begin marketing of the new products, consistent with all existing requirements of regulated tobacco products.

Japan Tobacco Inc Receives Manufacturing and Marketing Approval for Stribild Combination Tablets

Monday, 25 Mar 2013 02:00am EDT

Japan Tobacco Inc announced that it has received manufacturing and marketing approval of a novel anti-HIV drug, Stribild Combination Tablets, in Japan. The Company had filed a New Drug Application (NDA) for this drug with the Japanese Ministry of Health, Labour and Welfare in December 2012.

JAPAN TOBACCO INC and Torii Pharmaceutical Co., Ltd. File for New Drug Application for Marketing Approval of Hyperphosphatemia Remedy JTT-751 in Japan

Monday, 7 Jan 2013 01:00am EST

JAPAN TOBACCO INC announced that it has filed a new drug application (NDA) for marketing approval of a hyperphosphatemia remedy JTT-751 in Japan. If the application is approved, Torii Pharmaceutical Co., Ltd. will be in charge of the sale of the new drug.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: MarketLine (a Datamonitor Company)
$33.00
Provider: Pechala's Reports
$10.00
Provider: Wright Reports
$65.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.